Perphenazine
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682165 | 
| Pregnancy category | 
 | 
| Routes of administration | Oral and IM | 
| Drug class | Typical antipsychotic | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 40% | 
| Metabolism | hepatic | 
| Elimination half-life | 8–12 (up to 20) hours | 
| Identifiers | |
| 
 | |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.000.346 | 
| Chemical and physical data | |
| Formula | C21H26ClN3OS | 
| Molar mass | 403.97 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (verify) | |
Perphenazine is a typical antipsychotic drug. Chemically, it is classified as a piperazinyl phenothiazine. Originally marketed in the United States as Trilafon, it has been in clinical use for decades.
Perphenazine is roughly ten times as potent as chlorpromazine at the dopamine-2 (D2) receptor; thus perphenazine is considered a medium-potency antipsychotic.